Vaccination News Home Page

http://www.telegraph.co.uk/news/main.jhtml?xml=%2Fnews%2F2002%2F04%2F15%2Fnpox15.xml

| |
news.telegraph.co.uk
Save this page to your clipboard Email this page to a friend Print this page as text only
telegraph.co.uk
News home
Business news
Crossword Society
Feedback
Golden Jubilee
Law reports
Matt cartoon
Obituaries
Opinion
Weather
War on terrorism
About us
Contact us

 
 


 

Ministers rule out mass vaccination for smallpox
By David Millward
(Filed: 15/04/2002)
 

DETAILED plans to counter the use of smallpox in a biological attack by terrorists have been drawn up in Whitehall, but ministers have ruled out the re-introduction of mass vaccination.

Instead, the Government would create a series of "firewalls", treating those with the disease and inoculating people in direct or indirect contact with them to prevent smallpox spreading.

At the same time there is to be an international exercise next month to co-ordinate cross-border co-operation among members of the G7 group of industrial nations.

But the decision to buy 16 million doses of the vaccine was overshadowed by the controversy over the award of the £32 million contract to PowderJect after it emerged that Dr Paul Drayson, its chief executive, donated £50,000 to Labour nine months ago.

It left the Government embroiled in yet more damaging "cash for contracts" allegations. But it is understood that ministers chose PowderJect on military and security advice.

PowderJect is ready to make available the Lister strain of the vaccine, the same as that being developed for military use at the Ministry of Defence laboratory in Porton Down, Wilts.

Ministers were told that it would be advisable to ensure that the same strains were being used for military and civilian purposes.

But PowderJect's main rival, Acambis, which has won the contract to provide 92 million doses of the New York City strain of the vaccine, said it could have met British demand if the Government had not insisted on the Lister strain.

A spokesman for the Cambridge-based company said its version had been tested, but admitted that it would have taken Acambis two years to test and produce the doses of Lister vaccine.

The Government's decision to press ahead with buying doses of the Lister strain was endorsed by Colin Kaplan, Emeritus Professor of Microbiology at Reading University.

Prof Kaplan said that although there was little to choose between the Lister and New York strains, harmonising military and civilian policy was sensible.

He said he believed that the greatest threat was from bio-terrorism.

"If you believe that some form of biological warfare is in prospect, then having vaccine stocks is a sensible thing to do. Smallpox is destructive and easier to spread around than anthrax.

"All you have to do is smuggle someone on to the Tube with the virus. He then shakes a handkerchief."

Those nearby would feel ill after about 10 days and also start infecting others. But it would take around 14 days for smallpox to be diagnosed.

 

14 April 2002: Labour claims unravel over vaccine deal
14 April 2002: Iraq warnings prompt rush to order vaccine
13 April 2002: Tories demand probe into vaccine contract
13 April 2002: Britain buys up stocks of smallpox vaccine
13 April 2002: Why defeat of a scourge left world vulnerable
6 November 2001: Warning of smallpox terror risk
22 October 2001: Talks on medicines to fight bio-terrorism

 

 
External links  
 
War on terrorism - 10 Downing Street
 
PowderJect
 
Smallpox - World Health Organisation
 
What is smallpox - WEB MD
 
Bioterrorism - New Scientist
 
Smallpox as a biological weapon - JAMA
 

 

 

 

 

accination News Home Page

ALL INFORMATION, DATA, AND MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR LEGAL ADVICE.  THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH YOUR HEALTH CARE PROVIDER.